α-(pyridin-4-yl)benzyl chloride hydrochloride

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: α-(pyridin-4-yl)benzyl chloride hydrochloride
• 英文别名: α-(4-pyridyl)benzyl chloride hydrochloride；4-[Chloro(phenyl)methyl]pyridine hydrochloride；4-[chloro(phenyl)methyl]pyridine;hydrochloride
• 化学式: C₁₂H₁₀ClN*ClH
• 分子量: 240.132
• InChiKey: QCXRPPJCEMIESN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.83
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  12.9
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  苯基(4-吡啶基)甲醇 在 氯化亚砜 作用下， 以 二氯甲烷 为溶剂， 以89 mg的产率得到α-(pyridin-4-yl)benzyl chloride hydrochloride
  参考文献：
  名称：

  COMPOUNDS FOR TREATING VIRAL INFECTION

  摘要：

  The present invention relates generally to a compound and/or a composition comprising the compound, useful for the treatment of, or prevention of, a Coronavirus (CoV) infection in particular SARS-CoV/SARS-CoV-1 or SARS-CoV-2.

  公开号：

  WO2024124287A1

文献信息

• Acetamide derivatives and their use as feeding behaviour modifiers
  申请人：Laboratoire L. Lafon

  公开号：US05719168A1

  公开（公告）日：1998-02-17

  The present invention relates to compounds of formula (I) wherein R.sub.1 is selected from H and 3-chloro; R.sub.2 is selected from a phenyl group and a pyridyl group; R.sub.3 and R.sub.4 are selected independently of each other from H and methyl; R.sub.5 and R.sub.6 are selected independently of each other from H and a pyridyl-methyl group or both represent an ethyl group; n=0 or 1; R.sub.1, R.sub.3, R.sub.4, R.sub.5 and R.sub.6 are not simultaneously H when R.sub.2 is phenyl. The salts of the compounds have a pyridyl group with pharmaceutical acceptable acids are also disclosed.

  本发明涉及式（I）化合物，其中R.sub.1从H和3-氯中选择；R.sub.2从苯基和吡啶基中选择；R.sub.3和R.sub.4可独立地从H和甲基中选择；R.sub.5和R.sub.6可独立地从H和吡啶基-甲基或两者都代表乙基中选择；n=0或1；当R.sub.2为苯基时，R.sub.1、R.sub.3、R.sub.4、R.sub.5和R.sub.6不同时为H。还公开了含有药用可接受酸的化合物的吡啶基盐。
• MATRINIC ACID/ MATRINE DERIVATIVES AND PREPARATION METHODS AND USES THEREOF
  申请人：Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences

  公开号：EP2581376A1

  公开（公告）日：2013-04-17

  The present invention relates to a N-substituted matrinic acid derivative or matrine derivative, and its preparation method and uses. Specifically, the present invention relates to a compound of Formula (I) or (II) (wherein all the definitions of substituted groups are those mentioned in the specification), or a pharmaceutically acceptable salt, geometric isomer, stereoisomer, solvate, ester or prodrug thereof. The present invention further relates to a method for preparing the compound of the present invention, a pharmaceutical composition containing the compound, and uses thereof in manufacture of a medicament. The compound of the present invention can be used for prophylaxis and/or treatment of a disease or disorder associated with viral infection such as hepatitis B and/orhepatitis C and/orAIDS.

  本发明涉及一种 N-取代的马钱子酸衍生物或马钱子碱衍生物及其制备方法和用途。具体地说，本发明涉及一种式（I）或（II）化合物（其中所有取代基团的定义均为说明书中提及的定义），或其药学上可接受的盐、几何异构体、立体异构体、溶液、酯或原药。本发明还涉及一种制备本发明化合物的方法、一种含有本发明化合物的药物组合物及其在制造药物中的用途。本发明化合物可用于预防和/或治疗与病毒感染有关的疾病或紊乱，如乙型肝炎和/或丙型肝炎和/或艾滋病。
• US5719168A
  申请人：——

  公开号：US5719168A

  公开（公告）日：1998-02-17
• COMPOUNDS FOR TREATING VIRAL INFECTION
  申请人：[en]THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH

  公开号：WO2024124287A1

  公开（公告）日：2024-06-20

  The present invention relates generally to a compound and/or a composition comprising the compound, useful for the treatment of, or prevention of, a Coronavirus (CoV) infection in particular SARS-CoV/SARS-CoV-1 or SARS-CoV-2.